Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lipocine Inc.

NASDAQ: LPCN · Life Sciences · 10 alerts · CIK 1535955

Share price
$1.66Close, Nov 16
Market cap
$18.4M
Shares outstanding
11.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lipocine Inc. filings on SEC EDGAR ↗

3:24 PM ET Form 4
Insider Buying

Lipocine CEO Mahesh V. Patel Buys $79.5K of Stock

Mahesh V. Patel, CEO, bought 50,000 shares of Lipocine Inc. at $1.58 to $1.60 a share (average $1.59) in 2 transactions, worth $79.5K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 211,495 (+13.4%).

Value
$79.5K
Shares
50,000
Average price
$1.59
Role
CEO
Holding change
+13.4%
Trade date
Nov 12, 2026 to Nov 13, 2026
6:04 AM ET 8-K
Business Update

Lipocine Business Update

Lipocine Inc. announced the dosing of the first participant in its BLOOM Phase 3 study of LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is expected to enroll approximately 120 participants and incorporates design improvements from a previous Phase 3 trial, with topline results expected in the second half of 2027.

9:36 AM ET 8-K
Financial Results

Lipocine Financial Results

Lipocine Inc. reported financial results for the third quarter of 2026, highlighting a net loss of $0.7 million and a cash position of $21.5 million as of September 30, 2026. The company also provided clinical updates, including the initiation of the Phase 3 BLOOM study for LPCN 1154 (BRLIZIO) in postpartum depression and the approval of TLANDO in Canada.

Term
Q3 2026
9:31 AM ET 10-Q
Financial Results

Lipocine Q3 2026 Results: Net Loss of $666K, Loss Narrows

Lipocine Inc. reported total revenues of $2.6 million for the nine months ended September 30, 2026, driven by a $2.1 million license fee. Despite the revenue increase, the company incurred a net loss of $7.0 million due to higher operating expenses, though it maintains sufficient capital to fund operations through November 2027.

Key figure
Net loss $666K
7:47 AM ET 8-K
Investor Presentation

Lipocine Investor Presentation

Lipocine Inc. has updated its corporate presentation for use in meetings with investors, analysts, and other stakeholders. The presentation was filed as Exhibit 99.1 to the 8-K and provides a strategic overview of the company's business and development pipeline.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.